Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s12094-024-03540-2.pdf
Reference6 articles.
1. Ospina AV, Bolufer Nadal S, De La Campo-Cañaveral Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, De Calvo Juan V, Casal Rubio J, De Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clin Transl Oncol. 2024. https://doi.org/10.1007/s12094-024-03382-y.
2. Dickhoff C, Heineman D, Schneiders F, Houda I, Veltman J, Hashemi S, Fransen M, Radonic T, Bartelink I, Meijboom L, Oprea-Lager D, Bouwhuis N, De Gruijl T, Senan S, Bahce I. OA06.04 surgery after neoadjuvant immuno-chemoradiotherapy in (borderline) Resectable NSCLC: results from the INCREASE Trial. J Thorac Oncol. 2023;18:S56–7. https://doi.org/10.1016/j.jtho.2023.09.045.
3. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur W-D, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2872–80. https://doi.org/10.1200/JCO.21.00276.
4. Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:1124–8. https://doi.org/10.1016/j.jtho.2023.06.002.
5. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:181–93. https://doi.org/10.1016/j.jtho.2022.10.003.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3